| Literature DB >> 26640704 |
Salvatore Di Lauro1, Melissa Castrejón2, Itziar Fernández3, Jimena Rojas2, Rosa M Coco2, María R Sanabria4, Enrique Rodríguez de la Rua5, J Carlos Pastor1.
Abstract
Purpose. To quantify the frequency of visual loss after successful retinal detachment (RD) surgery in macula-on patients in a multicentric, prospective series of RD. Methods. Clinical variables from consecutive macula-on RD patients were collected in a prospective multicentric study. Visual loss was defined as at least a reduction in one line in best corrected visual acuity (VA) with Snellen chart. The series were divided into 4 subgroups: (1) all macula-on eyes (n = 357); (2) macula-on patients with visual loss at the third month of follow-up (n = 53) which were further subdivided in (3) phakic eyes (n = 39); and (4) pseudophakic eyes (n = 14). Results. Fifty-three eyes (14.9%) had visual loss three months after surgery (n = 39 phakic eyes; n = 14 pseudophakic eyes). There were no statistically significant differences between them regarding their clinical characteristics. Pars plana vitrectomy (PPV) was used in 67.2% of cases, scleral buckle in 57.7%, and scleral explant in 11.9% (36.1% were combined procedures). Conclusions. Around 15% of macula-on RD eyes lose VA after successful surgery. Development of cataracts may be one cause in phakic eyes, but vision loss in pseudophakic eyes could have other explanations such as the effect of released factors produced by retinal ischemia on the macula area. Further investigations are necessary to elucidate this hypothesis.Entities:
Year: 2015 PMID: 26640704 PMCID: PMC4660023 DOI: 10.1155/2015/821864
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Main preoperative characteristics in groups G2, G3, and G4.
| Eyes with reattached retina and visual loss (G2) | Phakic eyes with reattached retina and visual loss (G3) | Pseudophakic eyes with reattached retina and visual loss (G4) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| 95%CI |
|
| 95%CI |
|
| 95%CI |
| |
| Previous PVR | |||||||||
| No | 24 (45.3%) | 31.9%; 58.7% | 0.1166 | 19 (48.7%) | 32.7%; 65% | 0.3842 | 5 (35.7%) | 22.8%; 48.6% | 0.1832 |
| A | 17 (32.1%) | 19.5%; 44.6% | 0.2695 | 13 (33.3%) | 19.6%; 50.3% | 0.2799 | 4 (28.6%) | 16.4%; 40.7% | 0.9723 |
| B | 12 (22.6%) | 11.4%; 34% | 0.5488 | 7 (17.9%) | 8.1%; 34.1% | 1 | 5 (35.7%) | 22.8%; 48.6% | 0.1886 |
| Total | 53 (100%) | 39 (100%) | 14 (100%) | ||||||
| Retinal break | |||||||||
| Tear | 38 (71.7%) | 59.6%; 83.8% | 0.9803 | 28 (71.8%) | 54.9%; 84.5% | 1 | 10 (71.4%) | 59.3%; 83.6% | 1 |
| Hole | 12 (22.6%) | 11.4%; 33.9% | 0.8577 | 9 (23.1%) | 11.7%; 39.7% | 0.866 | 3 (21.4%) | 10.4%; 32.5% | 1 |
| Dialysis | 0 (0%) | 0%; 8.4% | 0.61 | 0 (0%) | 0%; 11.2% | 0.7774 | 0 (0%) | 0%; 26.8% | 1 |
| Giant tear | 2 (3.8%) | 0%; 8.9% | 1 | 1 (2.6%) | 0.1%; 15.1% | 0.9861 | 1 (7.1%) | 0.2%; 14.1% | 1 |
| Not visible | 1 (1.9%) | 0%; 5.6% | 1 | 1 (2.6%) | 0.1%; 15.1% | 1 | 0 (0%) | 0%; 26.8% | 1 |
| Total | 53 (100%) | 39 (100%) | 14 (100%) | ||||||
| Type of break | |||||||||
| Single | 27 (52.9%) | 39.2%; 66.6% | 0.7103 | 20 (52.6%) | 36.1%; 68.7% | 0.7509 | 7 (53.9%) | 40.2%; 67.5% | 1 |
| Multiple | 22 (43.1%) | 29.5%; 56.7% | 0.6979 | 16 (42.1%) | 26.7%; 59.1% | 0.8708 | 6 (46.2%) | 32.5%; 59.8% | 0.8359 |
| Posterior rupture | 1 (2%) | 0%; 5.8% | 1 | 1 (2.6%) | 0.1%; 15.4% | 0.9477 | 0 (0%) | 0%; 28.3% | 1 |
| Not visible | 1 (2%) | 0%; 5.8% | 1 | 1 (2.6%) | 0.1%; 15.4% | 1 | 0 (0%) | 0%; 28.3% | 1 |
| Total | 51 (100%) | 38 (100%) | 13 (100%) | ||||||
| Size of breaks (clock hours) | |||||||||
| Not visible | 1 (1.9%) | 0%; 5.7% | 0.9947 | 1 (2.6%) | 0.1%; 15.4% | 1 | 0 (0%) | 0%; 26.8% | 1 |
| 0-1 | 31 (59.6%) | 46.3%; 73% | 0.3571 | 22 (57.9%) | 40.9%; 73.3% | 0.3341 | 9 (64.3%) | 51.3%; 77.3% | 1 |
| 2-3 | 14 (26.9%) | 14.9%; 39% | 0.6371 | 11 (28.9%) | 16%; 46.1% | 0.5175 | 3 (21.4%) | 10.3%; 32.6% | 1 |
| >3 | 6 (11.5%) | 2.9%; 20.2% | 0.3815 | 4 (10.5%) | 3.4%; 25.7% | 0.6698 | 2 (14.3%) | 4.8%; 23.8% | 0.6357 |
| Total | 52 (100%) | 38 (100%) | 14 (100%) | ||||||
| Previous vitreous hemorrhage | |||||||||
| No | 44 (83%) | 72.9%; 93.1% | 0.6852 | 32 (82.1%) | 65.9%; 91.9% | 0.6451 | 12 (85.7%) | 76.3%; 95.1% | 1 |
| Yes | 9 (17%) | 6.9%; 27.1% | 0.6852 | 7 (17.9%) | 8.1%; 34.1% | 0.6451 | 2 (14.3%) | 4.9%; 23.7% | 1 |
| Total | 53 (100%) | 39 (100%) | 14 (100%) | ||||||
| Extension RD (quadrants) | |||||||||
| 0-1 | 21 (39.6%) | 26.5%; 52.8% | 0.9019 | 16 (41%) | 26%; 57.8% | 1 | 5 (35.7%) | 22.8%; 48.6% | 0.8724 |
| 2-3 | 32 (60.4%) | 47.2%; 73.6% | 0.9019 | 23 (59%) | 42.2%; 74% | 1 | 9 (64.3%) | 51.4%; 77.2% | 0.8724 |
| 4 | 0 (0%) | 0%; 8.4% | 1 | 0 (0%) | 0%; 11.2% | 1 | 0 (0%) | 0%; 26.8% | 1 |
| Total | 53 (100%) | 39 (100%) | 14 (100%) | ||||||
| Previous aphakic | |||||||||
| No | 39 (73.6%) | 61.7%; 85.5% | 0.6412 | 39 (100%) | 88.8%; 100% | 0.0001 | 0 (0%) | 0%; 26.8% | <0.0001 |
| Yes | 14 (26.4%) | 14.6%; 38.3% | 0.6412 | 0 (0%) | 0%; 11.2% | 0.0001 | 14 (100%) | 73.2%; 100% | <0.0001 |
| Total | 53 (100%) | 39 (100%) | 14 (100%) | ||||||
| PVD | |||||||||
| Unknown | 11 (20.8%) | 9.8%; 31.7% | 0.1176 | 8 (20.5%) | 9.9%; 36.9% | 0.1837 | 3 (21.4%) | 10.4%; 32.5% | 0.59 |
| No | 13 (24.5%) | 12.9%; 36.1% | 0.8361 | 10 (25.6%) | 13.6%; 42.4% | 0.7692 | 3 (21.4%) | 10.4%; 32.5% | 1 |
| Yes | 29 (54.7%) | 41.3%; 68.1% | 0.2562 | 21 (53.8%) | 37.4%; 69.6% | 0.4108 | 8 (57.1%) | 43.8%; 70.5% | 0.5698 |
| Total | 53 (100%) | 39 (100%) | 14 (100%) | ||||||
| Myopia | |||||||||
| No | 11 (27.5%) | 13.7%; 41.3% | 0.5078 | 9 (29%) | 14.9%; 48.2% | 0.719 | 2 (22.2%) | 9.3%; 35.1% | 0.707 |
| ≤5 Dp | 15 (37.5%) | 22.5%; 52.5% | 0.662 | 12 (38.7%) | 22.4%; 57.7% | 0.6276 | 3 (33.3%) | 18.7%; 47.9% | 1 |
| >5 Dp | 14 (35%) | 20.2%; 49.8% | 0.9518 | 10 (32.3%) | 17.3%; 51.5% | 1 | 4 (44.4%) | 29%; 59.8% | 0.722 |
| Total | 40 (100%) | 31 (100%) | 9 (100%) | ||||||
| Previous VA | |||||||||
| <20/100 | 0 (0%) | 0%; 8.4% | 0.0118 | 0 (0%) | 0%; 11.2% | 0.0362 | 0 (0%) | 0%; 26.8% | 0.32 |
| 20/100–20/40 | 9 (17%) | 6.9%; 27.1% | 0.4638 | 7 (17.9%) | 8.1%; 34.1% | 0.6659 | 2 (14.3%) | 4.9%; 23.7% | 0.702 |
| ≥20/40 | 44 (83%) | 72.9%; 93.1% | 0.0111 | 32 (82.1%) | 65.9%; 91.9% | 0.0449 | 12 (85.7%) | 76.3%; 95.1% | 0.1902 |
| Total | 53 (100%) | 39 (100%) | 14 (100%) | ||||||
Differences from G1: macula-on series.
n (%): number and percentage of patients in Retina 1 Project and macula-on groups G1, G2, G3, and G4. G1: macula-on group, G2: phakic and pseudophakic patients, G3: phakic patients, and G4: pseudophakic patients; CI: confidence interval; PVR: proliferative vitreoretinopathy; PVD: posterior vitreous detachment. VA: visual acuity, best corrected visual acuity.
Mean preoperative characteristics of the Retina 1 series included in the G1 group.
| Whole series (Retina 1) | Macula-on group (G1) |
| ||
|---|---|---|---|---|
|
|
| 95%CI | ||
| Previous PVR | ||||
| No | 522 (49.9%) | 203 (56.9%) | 51.7%; 62% | 0.0095 |
| A | 247 (23.6%) | 88 (24.7%) | 20.2%; 29.1% | 0.6823 |
| B | 278 (26.6%) | 66 (18.5%) | 14.5%; 22.5% | 0.0007 |
| Total | 1047 (100%) | 357 (100%) | ||
| Retinal break | ||||
| Tear | 739 (70.7%) | 252 (70.6%) | 65.9%; 75.3% | 1 |
| Hole | 223 (21.3%) | 74 (20.7%) | 16.5%; 24.9% | 0.8278 |
| Dialysis | 12 (1.2%) | 7 (2%) | 0.5%; 3.4% | 0.2346 |
| Giant tear | 37 (3.5%) | 14 (3.9%) | 1.9%; 5.9% | 0.805 |
| Not visible | 34 (3.3%) | 10 (2.8%) | 1.1%; 4.5% | 0.7421 |
| Total | 1045 (100%) | 357 (100%) | ||
| Type of break | ||||
| Single | 526 (52.1%) | 196 (56.5%) | 51.3%; 61.7% | 0.1164 |
| Multiple | 432 (42.8%) | 137 (39.5%) | 34.3%; 44.6% | 0.2306 |
| Posterior rupture | 17 (1.7%) | 4 (1.2%) | 0%; 2.3% | 0.5786 |
| Not visible | 34 (3.4%) | 10 (2.9%) | 1.1%; 4.6% | 0.7225 |
| Total | 1009 (100%) | 357 (100%) | ||
| Size of breaks (clock hours) | ||||
| Not visible | 34 (3.3%) | 10 (2.9%) | 1.1%; 4.6% | 0.7321 |
| 0-1 | 673 (65.4%) | 235 (66.6%) | 61.7%; 71.5% | 0.684 |
| 2-3 | 265 (25.8%) | 82 (23.2%) | 18.8%; 27.6% | 0.3067 |
| >3 | 57 (5.5%) | 26 (7.4%) | 4.6%; 10.1% | 0.1667 |
| Total | 1029 (100%) | 353 (100%) | ||
| Previous vitreous hemorrhage | ||||
| No | 908 (88%) | 304 (85.9%) | 82.3%; 89.5% | 0.2561 |
| Yes | 124 (12%) | 50 (14.1%) | 10.5%; 17.8% | 0.2561 |
| Total | 1032 (100%) | 354 (100%) | ||
| Extension RD (quadrants) | ||||
| 0-1 | 188 (18.1%) | 147 (41.4%) | 36.3%; 46.5% | <0.0001 |
| 2-3 | 736 (70.8%) | 208 (58.6%) | 53.5%; 63.7% | <0.0001 |
| 4 | 116 (11.2%) | 0 (0%) | 0%; 1.3% | <0.0001 |
| Total | 1040 (100%) | 355 (100%) | ||
| Macula | ||||
| On | 382 (36.7%) | 357 (100%) | 98.7%; 100% | <0.0001 |
| Off | 658 (63.3%) | 0 (0%) | 0%; 1.3% | <0.0001 |
| Total | 1040 (100%) | 357 (100%) | ||
| Previous aphakic | ||||
| No | 664 (63.5%) | 248 (69.7%) | 64.9%; 74.4% | 0.0179 |
| Yes | 382 (36.5%) | 108 (30.3%) | 25.6%; 35.1% | 0.0179 |
| Total | 1046 (100%) | 356 (100%) | ||
| PVD | ||||
| Unknown | 357 (34.1%) | 113 (31.7%) | 26.8%; 36.5% | 0.3578 |
| No | 193 (18.4%) | 80 (22.4%) | 18.1%; 26.7% | 0.0614 |
| Yes | 497 (47.5%) | 164 (46%) | 40.8%; 51.1% | 0.5985 |
| Total | 1047 (100%) | 357 (100%) | ||
| Myopia | ||||
| No | 346 (44.5%) | 94 (33.7%) | 28.1%; 39.2% | 0.0003 |
| ≤5 Dp | 206 (26.5%) | 92 (33%) | 27.5%; 38.5% | 0.0174 |
| >5 Dp | 225 (29%) | 93 (33.3%) | 27.8%; 38.9% | 0.1225 |
| Total | 777 (100%) | 279 (100%) | ||
| Preoperative VA | ||||
| <20/100 | 631 (61%) | 44 (12.3%) | 8.9%; 15.7% | <0.0001 |
| 20/100–20/40 | 142 (13.7%) | 79 (22.1%) | 17.8%; 26.4% | <0.0001 |
| ≥20/40 | 261 (25.2%) | 234 (65.6%) | 60.6%; 70.5% | <0.0001 |
| Total | 1034 (100%) | 357 (100%) | ||
n (%): number and percentage of patients in Retina 1 Project and macula-on group (G1); G1: macula-on group; CI: confidence Interval; PVR: proliferative vitreoretinopathy; PVR grades A and B as defined by the Retina Society Classification in 1983; PVD: posterior vitreous detachment; RD: retinal detachment; VA: visual acuity, best corrected visual acuity.
Variation in visual acuity in G3 before surgery and at the end of the follow-up period.
| VA | Preoperative VA | Postoperative VA | ||
|---|---|---|---|---|
|
| 95%CI |
| 95%CI | |
| <20/100 | 0 (0%) | 0%; 11.2% | 12 (30.8%) | 17.6%; 47.7% |
| 20/100–20/40 | 7 (17.9%) | 8.1%; 34.1% | 27 (69.2%) | 52.3%; 82.5% |
| >20/40 | 32 (82.1%) | 65.9%, 91.9% | 0 (0%) | 0%; 11.2% |
| Total | 39 (100%) | 39 (100%) | ||
G3: phakic eyes with visual loss at third month of follow-up; VA: best visual acuity corrected at the end of the follow-up (Snellen chart).
Variation in visual acuity in G4 before surgery and at the end of the follow-up.
| VA | Preoperative VA | Postoperative VA | ||
|---|---|---|---|---|
|
| 95%CI |
| 95%CI | |
| <20/100 | 0 (0%) | 0%; 26.8% | 7 (50%) | 36.5%; 63.5% |
| 20/100–20/40 | 2 (14.3%) | 4.9%; 23.7% | 7 (50%) | 36.5%; 63.5% |
| >20/40 | 12 (85.7%) | 76.3%; 95.1% | 0 (0%) | 0%; 26.8% |
| Total | 14 (100%) | 14 (100%) | ||
G4: pseudophakic eyes with visual loss at third month of follow-up; VA: best visual acuity corrected at the end of the follow-up (Snellen chart).